<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04141020</url>
  </required_header>
  <id_info>
    <org_study_id>20190857</org_study_id>
    <secondary_id>1R01NS111119-01A1</secondary_id>
    <nct_id>NCT04141020</nct_id>
  </id_info>
  <brief_title>Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms</brief_title>
  <official_title>Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to explore the effects of Sirolimus on the underlying
      molecular alterations of cerebral aneurysms.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in gene expression from control arteries.</measure>
    <time_frame>Day 18</time_frame>
    <description>Change in gene expressions will be reported as fold change from control arteries: superficial temporal artery from the same patient and the intracerebral temporal lobe artery from a different patient. Genes to be evaluated are endothelial cell marker genes such as Cluster of Differentiation (CD) 34, CD31, Von Willebrand Factor (vWF), E-selectin, Vascular Endothelial (VE)-cadherin and Endothelial Nitric Oxide Synthase (eNOS) and pro-inflammatory-matrix remodeling proliferation genes such as Matrix Metallopeptidase (MMP)3 and MMP9, Vascular Cell Adhesion Molecule (VCAM)-1, Intercellular Adhesion Molecule (ICAM), Inducible Nitric Oxide Synthase (iNOS), Membrane Cofactor Protein (MCP) and Interleukin (IL)-1ß.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in gene expression between blood samples.</measure>
    <time_frame>Day 18</time_frame>
    <description>Change in gene expressions will be reported as fold change of intra-aneurysmal blood to peripheral blood from the same patient. Genes to be evaluated are endothelial cell marker genes (CD34, CD31, vWF, E-selectin, VE-cadherin, and eNOS) and pro-inflammatory-matrix remodeling proliferation genes (MMP3, MMP9, VCAM-1, ICAM, iNOS, MCP, and IL-1ß).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in gene expression.</measure>
    <time_frame>Day 18</time_frame>
    <description>Fold change of IL-2 expression and expression of endothelial cell marker genes (CD34, CD31, vWF, E-selectin, VE-cadherin, and eNOS) and pro-inflammatory-matrix remodeling proliferation genes (MMP3, MMP9, VCAM-1, ICAM, iNOS, MCP, and IL-1ß) will be evaluated between sirolimus treated to non-treated patients.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cerebral Aneurysm</condition>
  <arm_group>
    <arm_group_label>Microsurgical Clipping Treated with Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergoing standard of care microsurgical clipping of unruptured cerebral aneurysm will be treated with 2 mg Sirolimus daily for 14-18 consecutive days prior to surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endovascular Treatment Treated with Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergoing standard of care endovascular treatment of unruptured cerebral aneurysm procedure will be treated with 2 mg Sirolimus daily for 14-18 consecutive days prior to procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microsurgical clipping</intervention_name>
    <description>Standard of care microsurgical clipping of an unruptured cerebral artery aneurysm.</description>
    <arm_group_label>Microsurgical Clipping Treated with Sirolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endovascular treatment</intervention_name>
    <description>Standard of care endovascular treatment of an unruptured cerebral artery aneurysm.</description>
    <arm_group_label>Endovascular Treatment Treated with Sirolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Daily oral Sirolimus 2 mg tablets, adjusted as necessary per treating physician.</description>
    <arm_group_label>Endovascular Treatment Treated with Sirolimus</arm_group_label>
    <arm_group_label>Microsurgical Clipping Treated with Sirolimus</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Undergoing one of the following procedures at Jackson Memorial Hospital:

               -  Clipping of an unruptured cerebral artery aneurysm

               -  Endovascular treatment of unruptured cerebral aneurysms (including those
                  receiving coiling)

          2. ≥ 18 years of age

          3. Willing and able to give informed consent

        Exclusion Criteria:

        1) Subjects meeting any of the following criteria will be excluded:

          -  Dissecting, traumatic, or mycotic brain aneurysm.

          -  Women who are pregnant, or have a positive urine or blood (β-hCG) pregnancy test.

          -  Women who are breastfeeding.

          -  Any clinically significant psychiatric or psychological disease, which would preclude
             the patient from completing the protocol.

          -  Patients with known Human Immunodeficiency Virus (HIV) infection or other known
             immunodeficiency.

          -  Patient with renal or liver failure

          -  Interstitial pneumonitis

          -  History of lymphoma

          -  History of skin cancer

          -  Hypersensitivity to sirolimus

          -  Severe or unstable concomitant condition disease or chronic condition, which in the
             opinion of the investigator could affect assessment of the safety or efficacy of study
             intervention.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert M Starke, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lutecia M Pereira, Ph.D</last_name>
    <phone>305-243-3806</phone>
    <email>lpereira@miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lutecia M Pereira, Ph.D</last_name>
      <phone>305-243-3806</phone>
      <email>lpereira@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Robert M Starke, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 24, 2019</study_first_submitted>
  <study_first_submitted_qc>October 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Robert Starke</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

